Added to YB: 2025-07-29
Pitch date: 2025-07-25
MRVI [neutral]
Maravai LifeSciences Holdings, Inc.
+35.93%
current return
Author Info
Two Natural Capital writes about markets, particularly focused on life sciences/biotech. Sign up for the newsletter.
Company Info
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America.
Market Cap
$527.9M
Pitch Price
$2.70
Price Target
N/A
Dividend
N/A
EV/EBITDA
-12.75
P/E
-4.32
EV/Sales
4.36
Sector
Life Sciences Tools and Services
Category
N/A
Maravai: Can an mRNA Capping Provider Move Beyond Covid? $mrvi
MRVI (pass): Life science supplier specializing in mRNA capping (CleanCap, 72% of NAP rev) & biologics safety testing. NAP declined from $883M (2022) to $259M (2024) post-COVID. Faces headwinds in non-COVID mRNA adoption despite high capping efficiency (95%). Future depends on broader mRNA applications, but faces Danaher competition & lower pricing.
Read full article (9 min)